天瑞儀器(300165.SZ)2020年度淨利潤預降12%-40%
格隆匯 1 月 22日丨天瑞儀器(300165.SZ)公佈,預計2020年度歸屬於上市公司股東的淨利潤1263.3萬元-1852.85萬元,同比下降12%-40%;扣除非經常性損益後的淨虧損2970.84萬元-3560.39萬元。
2020年度公司歸屬於上市公司股東的淨利潤較上年同期下降40%-12%,主要原因是:1、子公司上海磐合科學儀器股份有限公司、上海貝西生物科技有限公司受疫情影響,銷售訂單減少,影響當期利潤;2、銷售回款未達預期,計提信用減值損失-壞賬損失增加;綜述以上兩方面原因由此導致公司本期經營業績下降,淨利潤同比去年減少。
報吿期內,公司非經常性損益對淨利潤影響額預計為4800萬元左右。主要來自於非流動資產處置收益和政府補助。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.